Clinical trials for enfuvirtide  (Fuzeon, T-20).
Crabb
Charlene
C
D017088:AIDS-Related Opportunistic Infections / Q000139:chemically induced; D017326:Clinical Trials, Phase III as Topic; D003365:Costs and Cost Analysis; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000139:chemically induced
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide